ATE526019T1 - Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen - Google Patents

Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen

Info

Publication number
ATE526019T1
ATE526019T1 AT01972917T AT01972917T ATE526019T1 AT E526019 T1 ATE526019 T1 AT E526019T1 AT 01972917 T AT01972917 T AT 01972917T AT 01972917 T AT01972917 T AT 01972917T AT E526019 T1 ATE526019 T1 AT E526019T1
Authority
AT
Austria
Prior art keywords
treating cell
cell proliferation
virus infections
proliferation disorders
viral infections
Prior art date
Application number
AT01972917T
Other languages
English (en)
Inventor
Rosen Neal
Srethapakdi Mary
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26915764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE526019(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE526019T1 publication Critical patent/ATE526019T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01972917T 2000-07-28 2001-07-27 Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen ATE526019T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22141500P 2000-07-28 2000-07-28
US24526400P 2000-11-02 2000-11-02
PCT/US2001/023640 WO2002009696A1 (en) 2000-07-28 2001-07-27 Methods for treating cell proliferative disorders and viral infections

Publications (1)

Publication Number Publication Date
ATE526019T1 true ATE526019T1 (de) 2011-10-15

Family

ID=26915764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972917T ATE526019T1 (de) 2000-07-28 2001-07-27 Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen

Country Status (8)

Country Link
US (1) US6946456B2 (de)
EP (1) EP1322307B1 (de)
JP (1) JP2004505044A (de)
KR (1) KR20030046397A (de)
AT (1) ATE526019T1 (de)
AU (2) AU9254801A (de)
CA (1) CA2417495C (de)
WO (1) WO2002009696A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1335920B1 (de) * 2000-11-02 2013-04-03 Sloan-Kettering Institute For Cancer Research Purinderivate enthaltende zusammensetzungen zur bindung an hsp90
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
CA2474508A1 (en) 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
WO2003079936A1 (en) * 2002-03-18 2003-10-02 Medtronic Ave Inc. Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis
JP2005528390A (ja) * 2002-04-10 2005-09-22 コンフォーマ・セラピューティクス・コーポレイション アンサマイシン製剤およびその製造ならびに使用方法
US7138402B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation Pyrrolopyrimidines and related analogs as HSP90-inhibitors
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
CA2539651A1 (en) * 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Synthetic lethal screen using rna interference
EP2492261B1 (de) 2003-12-23 2015-02-18 Infinity Discovery, Inc. Analoga von benzochinonhaltigen Ansamycinen zur Behandlung von Krebs
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
CN101072759B (zh) * 2004-11-18 2013-06-19 Synta医药公司 调节hsp90活性的三唑化合物
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2598239C (en) * 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
JP2008534609A (ja) 2005-03-30 2008-08-28 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体
US20060228405A1 (en) * 2005-04-07 2006-10-12 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
CA2613632A1 (en) 2005-06-29 2007-01-04 Shinpei Yamaguchi Benzenoid ansamycin derivative
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CN101360492A (zh) * 2005-12-01 2009-02-04 康福玛医药公司 含安莎霉素的组合物
DK1971338T3 (da) * 2005-12-22 2011-05-23 Astrazeneca Ab Kombination af ZD6474 og pemetrexed
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
AU2007267852A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate Hsp90 activity and methods for identifying same
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
CA2696021C (en) * 2006-08-11 2015-09-29 Nicolas Winssinger Macrocyclic compounds useful as inhibitors of kinases and hsp90
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
CA2679126A1 (en) 2007-03-01 2008-09-04 Chugai Seiyaku Kabushiki Kaisha Macrocyclic compound
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
BRPI0906598A2 (pt) 2008-02-01 2015-07-07 Takeda Pharmaceutical Oxim derivattivos como inibidores hsp90
US20110230499A1 (en) * 2008-11-28 2011-09-22 Novartis Ag Hsp90 inhibitors for therapeutic treatment
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP2560640A1 (de) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3595955A (en) 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
KR920000763A (ko) * 1990-06-06 1992-01-29 가와무라 요시부미 라디시콜 유도체, 그 제조방법 및 그의 항종양 활성
US5650430A (en) * 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5731343A (en) * 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
CN1211244A (zh) 1996-10-25 1999-03-17 协和发酵工业株式会社 根赤壳菌素衍生物
DE69841549D1 (de) * 1997-05-14 2010-04-22 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US6413975B1 (en) 1999-04-02 2002-07-02 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase iv inhibition activity
WO2000061578A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
US6335157B1 (en) 1999-05-07 2002-01-01 The European Molecular Biology Laboratory Method based on localization of Hsp90 to the centrosome
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
EP1322325A4 (de) * 2000-07-20 2004-09-15 Merck & Co Inc Inhibition der prozessierung und replikation des hepatitis c virus
WO2002036171A1 (en) * 2000-11-02 2002-05-10 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors

Also Published As

Publication number Publication date
KR20030046397A (ko) 2003-06-12
AU2001292548B2 (en) 2005-06-16
WO2002009696A1 (en) 2002-02-07
EP1322307A4 (de) 2008-08-13
EP1322307A1 (de) 2003-07-02
CA2417495C (en) 2013-04-30
CA2417495A1 (en) 2002-02-07
AU9254801A (en) 2002-02-13
US6946456B2 (en) 2005-09-20
JP2004505044A (ja) 2004-02-19
EP1322307B1 (de) 2011-09-28
US20030216369A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
ATE526019T1 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
DE60229059D1 (de) Proteomimetische verbindungen und verfahren
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1062226T3 (da) Nukleinsyreligander med høj affinitet mod komplementsystemets C5-protein
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE69931377D1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
WO2002069900A3 (en) Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
DE60039415D1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
ATE519862T1 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
DK1278868T3 (da) Muteret form af arginindeiminase
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
BRPI0412441A (pt) método para estabilizar um crioprecipitado de proteìnas plasmáticas para ser submetido a um tratamento térmico de inativação viral
ATE128128T1 (de) Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE384263T1 (de) Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties